Rsv Lower Respiratory Tract Infection

Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial virus vaccine in 2023-2024, the first season in which they were available, according to study findings.

A new tool could help pediatricians identify infants most at risk for severe respiratory syncytial virus, according to research published in Open Forum Infectious Diseases.